Regulatory Approval (ANDA)

Lupin Receives U.S. FDA Approval for Famotidine Injection USP

NSE

lupin

BSE

500257

Lupin Limited has received U.S. FDA approval for its abbreviated new drug application (ANDA) for Famotidine Injection USP, a generic version of Pepcid Injection, with estimated annual U.S. market sales of USD 8.7 million.

PRICE-SENSITIVE TRIGGER

Event: U.S. FDA Drug Approval

Type: Regulatory Approval (ANDA)

Impact: Positive

Immediate Effect: The approval strengthens Lupin’s U.S. generics portfolio and supports incremental revenue opportunities in the injectable pharmaceuticals segment.

Key Metrics:

Estimated U.S. Annual Market Size: USD 8.7 Million
Approved Product: Famotidine Injection USP, 20 mg/2 mL (10 mg/mL)
Reference Drug: Pepcid Injection by Merck Sharp & Dohme Corp.
Manufacturing Facility: Nagpur Facility, India
Dosage Form: Single-Dose Vials

Highlight:

Label: U.S. FDA Approval
Value: Approval received for Famotidine Injection USP in the U.S. market

What Happened ?

Lupin Limited announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its abbreviated new drug application for Famotidine Injection USP.

The approved product is bioequivalent to Pepcid Injection and is indicated for treatment of several gastrointestinal conditions including ulcers, GERD, and pathological hypersecretory disorders. The product will be manufactured at Lupin’s Nagpur facility in India.

key highlights

Product & Regulatory Details:

Lupin received U.S. FDA approval for Famotidine Injection USP.
The product is a generic equivalent of Pepcid Injection.
The injection is used for treatment of ulcers, GERD, and hypersecretory conditions.
The approved formulation is 20 mg/2 mL (10 mg/mL) single-dose vials.
Manufacturing will take place at Lupin’s Nagpur manufacturing facility.
Estimated annual U.S. sales for the product stand at USD 8.7 million based on IQVIA MAT March 2026 data.
The approval enhances Lupin’s injectable portfolio in the regulated U.S. market.

Note:

U.S. FDA approvals remain strategically important for Indian pharmaceutical companies as they improve product pipeline strength and support export-driven growth.

Risk Analysis

Key Risks

Pricing pressure in the U.S. generics market may impact margins.
Competition from other generic manufacturers could limit market share gains.
Regulatory compliance and supply continuity remain critical.
Currency fluctuations may affect export profitability.
Demand ramp-up may take time depending on hospital procurement cycles.

Worst Case Scenario

Aggressive competition and pricing erosion in the U.S. injectable market could reduce the expected commercial benefit from the approval.

Risk Level: Medium

Company Commentary

Lupin stated that it has received U.S. FDA approval for Famotidine Injection USP.
The company confirmed that the product is bioequivalent to Pepcid Injection.
Lupin said the product will be manufactured at its Nagpur facility in India.
Management highlighted that estimated annual U.S. sales for the product are approximately USD 8.7 million.

Official Exchange Filing: Lupin Limited